4D Molecular Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 13.02, 19.8, 52.33, 126.77, 300.82 ], "ebit_estimate": [ -300.02, -334.61, -368.78, -349.13, -231.48 ], "ebitda_estimate": [ -296.39, -336.53, -378.65, null, null ], "net_income_estimate": [ -278.5, -314.5, -339.38, -328.54, -210.76 ], "per_share_eps_estimate": [ -4.24, -4.26, -4.24, -4.41, -2.93 ], "eps_nri_estimate": [ -4.04, -4.04, -3.92, -3.53, -2.16 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 3.62, 3.06, 1.33, null, null ], "pretax_income_estimate": [ -281.56, -319.5, -350.22, -328.54, -210.76 ], "operating_cash_flow_per_share_estimate": [ -3.72, -4, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -74.71, -122.06, -158.22, null, null ], "gross_margin_estimate": [ 2, 2, 3, 38, null ], "operating_cash_flow_estimate": [ -253.2, -272.26, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": -15.52, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -18.38, "future_eps_nri_estimate_growth": -15.52, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -29.99, "future_ebitda_estimate_growth": -32.44, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -31.99, "future_pretax_income_estimate_growth": -33.31, "future_book_value_per_share_estimate_growth": -44.17, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -77.41, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612" ], "revenue_estimate": [ 3.72, 3.8, 4.48 ], "ebit_estimate": [ -74.11, -74.89, -76.18 ], "ebitda_estimate": [ -71.75, -73.51, -76.71 ], "net_income_estimate": [ -70.16, -70.89, -71.57 ], "per_share_eps_estimate": [ -1.07, -1.07, -1.02 ], "eps_nri_estimate": [ -1.01, -1.01, -1 ], "dividend_estimate": [ null, null, null ], "book_value_per_share_estimate": [ null, null, null ], "pretax_income_estimate": [ -70.38, -70.63, -71.22 ], "operating_cash_flow_per_share_estimate": [ null, null, null ], "roa_estimate": [ null, null, null ], "roe_estimate": [ null, null, null ], "gross_margin_estimate": [ null, null, null ], "operating_cash_flow_estimate": [ null, null, null ], "pettm_estimate": [ null, null, null ], "long_term_growth_rate_mean": -15.52, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -18.38, "future_eps_nri_estimate_growth": -15.52, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -29.99, "future_ebitda_estimate_growth": -32.44, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -31.99, "future_pretax_income_estimate_growth": -33.31, "future_book_value_per_share_estimate_growth": -44.17, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -77.41, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }